ALNY vs MRK · P/E 76, rev $1.29B vs P/E 33, rev $16.61B
Alnylam Pharmaceuticals Inc (ALNY) versus Merck & Company Inc (MRK) — a side-by-side from cached financials, not a winner call.
Alnylam Pharmaceuticals Inc (ALNY) is a biotechnology company listed on US.
Merck & Company Inc (MRK) is a drug manufacturers - general company listed on NYSE. It is led by Robert M. Davis J.D..
Latest reported ALNY revenue for 2026-06-30 was $1.29B. Net income was $164.5M. Revenue was up 3.4% from 2025-09-30 to 2026-06-30. ALNY currently screens at market cap $40.46B and trailing P/E 76.3.
Latest reported MRK revenue for 2026-06-30 was $16.61B. Net income was -$1.33B. Revenue was up 2.0% from 2026-03-31 to 2026-06-30. MRK currently screens at market cap $285.12B and trailing P/E 32.5.
ALNY currently screens at market cap $40.46B and trailing P/E 76.3. MRK currently screens at market cap $285.12B and trailing P/E 32.5.
Not investment advice. Open the ALNY and MRK stock pages for the full models.
Not investment advice.